Stockscreener 앱 받기
3.44
7.50%
0.24
시간 외 거래:
3.43
-0.010
-0.29%
4 D Molecular Therapeutics Inc 주식(FDMT)의 최신 뉴스
Dimensional Fund Advisors LP Cuts Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4DMT Announces New Employment Inducement Grants - TradingView
FY2025 EPS Estimates for FDMT Decreased by Cantor Fitzgerald - Defense World
HC Wainwright Analysts Boost Earnings Estimates for FDMT - Defense World
Chardan Adjusts Price Target on 4D Molecular Therapeutics to $25 From $28, Maintains Buy Rating - marketscreener.com
Hsbc Holdings PLC Grows Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Barclays Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $38.00 - Defense World
Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $25.00 - Defense World
The Goldman Sachs Group Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $44.00 - Defense World
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
Wells Fargo & Company MN Boosts Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
Contrasting Genfit (NASDAQ:GNFT) & 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Sto - GuruFocus
RBC Cuts Price Target on 4D Molecular Therapeutics to $26 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Barclays PLC - The AM Reporter
Barclays Adjusts Price Target for 4D Molecular (FDMT) | FDMT Stock News - GuruFocus
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $26.71 Consensus Price Target from Brokerages - Defense World
4D Molecular Therapeutics Reports Increased Quarterly Loss - TipRanks
4D Molecular Therapeutics Inc Reports Q1 2025 EPS of -$0.86, Missing Estimates; Revenue Falls Short at $14,000 - GuruFocus
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics, Inc. SEC 10-Q Report - TradingView
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trials for 4D-150 in Wet AMD, Receives FDA RMAT Designation for DME - Nasdaq
4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - GlobeNewswire
FDMT4D Molecular Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - Yahoo Finance
Raymond James Financial Inc. Invests $629,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Gene Therapy in Ophthalmology Industry Report 2025-2035: Global Market Poised for Growth as Inherited Retinal Disease Cases Surge Worldwide - GlobeNewswire Inc.
Financial Comparison: 4D Molecular Therapeutics (NASDAQ:FDMT) and Cardiff Oncology (NASDAQ:CRDF) - Defense World
4D Molecular Therapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Are 4D Molecular Therapeutics Inc’shares a good deal? - uspostnews.com
Synhale Therapeutics Acquires Telaglenastat, Accelerates Development for Pulmonary Hypertension Treatment - The Malaysian Reserve
4D Molecular's Macular Edema Treatment Gets Regenerative Medicine Designation from FDA - marketscreener.com
4D Molecular Therapeutics' 4D-150 Receives RMAT Designation For Diabetic Macular Edema - Nasdaq
4D Molecular wins RMAT status for eye therapy (FDMT:NASDAQ) - Seeking Alpha
4D Molecular Therapeutics receives RMAT designation for 4D-150 for the treatment of diabetic macular edema - Ophthalmology Times
4D Molecular Therapeutics Receives FDA RMAT Designation for 4D-150 in Diabetic Macular Edema - Nasdaq
FDA grants RMAT status to 4D Molecular’s DME therapy - Investing.com Australia
4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME - GlobeNewswire
4D Molecular Therapeutics (FDMT) Expected to Announce Quarterly Earnings on Thursday - Defense World
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor - Quantisnow
X-linked retinitis pigmentosa Pipeline Analysis and Clinical - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by Geode Capital Management LLC - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings - Defense World
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - The Globe and Mail
4D Molecular Therapeutics Inc [FDMT] Shares Rise 0.59 % on Wednesday - knoxdaily.com
Retinitis Pigmentosa Drugs Market 2034: EMA, PDMA, FDA Approvals Clinical Trials, Prevalence, Medication, Revenue, Statistics, Pipeline and Companies by DelveInsight - The Globe and Mail
American Express Just Delivered Fantastic News for Investors. Here's Why the Warren Buffett Stock Is a Buy Now. - The Globe and Mail
Orion Mine Finance selling at Allied Gold (AAUC) - The Globe and Mail
How should investors view 4D Molecular Therapeutics Inc (FDMT)? - uspostnews.com
Lululemon Stock Analysis: I Highlight 3 Risks Investors Should Know and Update My Recommendation - The Globe and Mail
Discover Fractyl Health And 2 More Promising Penny Stocks - simplywall.st
Analyzing 4D Molecular Therapeutics (NASDAQ:FDMT) & Gilead Sciences (NASDAQ:GILD) - Defense World
JPMorgan Chase & Co. Raises Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
What is Leerink Partnrs’ Estimate for FDMT FY2026 Earnings? - Defense World
Vanguard Group Inc. Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
Retinitis Pigmentosa Market Growth to Accelerate in Forecast - openPR.com
1.54%
7.58%
자본화:
|
볼륨(24시간):